Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canfosfamide

X
Drug Profile

Canfosfamide

Alternative Names: Telcyta; TER 286; TLK 286

Latest Information Update: 10 Jul 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telik
  • Class Antineoplastics; Oligopeptides; Small molecules
  • Mechanism of Action Glutathione transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 10 Jul 2013 Canfosfamide is still available for licensing. http://www.telik.com
  • 05 Apr 2013 Telik terminates phase II trial in Diffuse large B cell lymphoma, Mantle cell lymphoma and Multiple myeloma in the USA (NCT01148108)
  • 31 Mar 2013 Suspended - Phase-II for Diffuse large B cell lymphoma in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top